MedTrace Logo

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

NCT02876302 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2026-02-04

Study results available
· View outcomes & findings →

Summary

This research study is studying Ruxolitinib as possible treatment for Inflammatory Breast Cancer (IBC).

The Following drugs will be use in combination with Ruxolinitinib.

* Paclitaxel (also called Taxol)
* Doxorubicin also called Adriamycin
* Cyclophosphamide, also called Cytoxan

Conditions

  • Inflammatory Breast Cancer (IBC)

Interventions

DRUG

Ruxolitinib

15 or 20 mg, twice daily by mouth. The run-in part of ruxolitinib lasts 7 days; The treatment of ruxolitinib part lasts 12 weeks.

DRUG

Paclitaxel

80 mg/m2, IV (in the vein) weekly for 12 weeks.

DRUG

Doxorubicin

60 mg/m2, IV (in the vein) every 14 days for 4 doses.

DRUG

Cyclophosphamide

600 mg/m2, IV (in the vein) every 14 days for 4 doses.

Sponsors & Collaborators

Principal Investigators

  • Filipa Lynce, MD · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-24
Primary Completion
2022-12-31
Completion
2026-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02876302 on ClinicalTrials.gov